Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Proteomics Clin Appl ; 3(1): 78-82, 2009 Jan.
Article in English | MEDLINE | ID: mdl-21136937

ABSTRACT

We report an approach for multiplex analysis of cancer biomarkers based on the measurement of diagnostic peptides in whole tissue protein digests. Label-free quantitation with MS3 multiple reaction monitoring (MRM) was developed to afford accurate analysis of prospective marker peptides in a panel of breast tumors. This approach provides an economical and robust alternative to stable isotope-based methods. It is equally applicable to the analysis of samples derived from tissue biopsy, aspirate, or plasma and can be easily translated to clinic.

2.
J Proteome Res ; 7(4): 1458-69, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18257521

ABSTRACT

We have conducted proteome-wide analysis of fresh surgery specimens derived from breast cancer patients, using an approach that integrates size-based intact protein fractionation, nanoscale liquid separation of peptides, electrospray ion trap mass spectrometry, and bioinformatics. Through this approach, we have acquired a large amount of peptide fragmentation spectra from size-resolved fractions of the proteomes of several breast tumors, tissue peripheral to the tumor, and samples from patients undergoing noncancer surgery. Label-free quantitation was used to generate protein abundance maps for each proteome and perform comparative analyses. The mass spectrometry data revealed distinct qualitative and quantitative patterns distinguishing the tumors from healthy tissue as well as differences between metastatic and non-metastatic human breast cancers including many established and potential novel candidate protein biomarkers. Selected proteins were evaluated by Western blotting using tumors grouped according to histological grade, size, and receptor expression but differing in nodal status. Immunohistochemical analysis of a wide panel of breast tumors was conducted to assess expression in different types of breast cancers and the cellular distribution of the candidate proteins. These experiments provided further insights and an independent validation of the data obtained by mass spectrometry and revealed the potential of this approach for establishing multimodal markers for early metastasis, therapy outcomes, prognosis, and diagnosis in the future.


Subject(s)
Breast Neoplasms/metabolism , Electrophoresis, Polyacrylamide Gel/methods , Proteome/analysis , Spectrometry, Mass, Electrospray Ionization/methods , Biomarkers, Tumor/analysis , Blotting, Western , Breast Neoplasms/pathology , Chemokine CCL1/analysis , Chromatography, Liquid/methods , Cluster Analysis , Computational Biology , DNA-Binding Proteins/analysis , Female , Homeodomain Proteins/analysis , Humans , Membrane Proteins/analysis , Microfilament Proteins/analysis , Microfluidic Analytical Techniques , Nanog Homeobox Protein , Nanotechnology , Proteomics/methods , Reproducibility of Results , STAT1 Transcription Factor/analysis , Thymidine Phosphorylase/analysis , Up-Regulation
4.
J Clin Oncol ; 20(4): 1026-35, 2002 Feb 15.
Article in English | MEDLINE | ID: mdl-11844826

ABSTRACT

PURPOSE: To determine biologic differences, if any, between presurgical endocrine treatment with an aromatase inhibitor (vorozole) and tamoxifen in patients with postmenopausal primary breast cancer. PATIENTS AND METHODS: Randomization was to 12 weeks of 2.5 mg of vorozole per day or 20 mg of tamoxifen per day, both orally. Clinical response was assessed monthly together with serum sex hormone binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), estrogens (E1, E2, and E1S), lipids, insulin-like growth factor-1 (IGF-1), and bone metabolites (CrossLaps CTx). Tissue samples for Ki67, apoptotic index (AI), estrogen receptor, and progesterone receptor were collected at 0, 2, and 12 weeks. RESULTS: Ki67 fell by 58% and 43% (means) at 2 weeks in the vorozole and tamoxifen patients, respectively (P =.13). In the vorozole group, the correlations of proportional changes in Ki67 at 2 weeks with tumor volume changes and clinical response at 12 weeks were not significant (P =.09) and marginally significant (P =.04), respectively. Serum lipids did not differ between groups. Serum levels of EI, E2, and E1S were suppressed markedly by vorozole, whereas levels of SHBG increased and LH and FSH fell significantly with tamoxifen. IGF-1 levels fell significantly with tamoxifen (P =.001) compared with the nonsignificant rise with vorozole. Twelve-week CTx values fell by 19% with tamoxifen (P =.006) and rose by 11% with vorozole (P =.15). CONCLUSION: The correlation with vorozole of Ki67 with volume and clinical response supports this as an intermediate marker. The nonsignificant effects on bone and lipid metabolism by the aromatase inhibitor may be important to consider for adjuvant and potential prevention strategies.


Subject(s)
Antineoplastic Agents, Hormonal/pharmacology , Biomarkers, Tumor/analysis , Breast Neoplasms/drug therapy , Enzyme Inhibitors/pharmacology , Ki-67 Antigen/analysis , Tamoxifen/pharmacology , Triazoles/pharmacology , Administration, Oral , Aged , Antineoplastic Agents, Hormonal/administration & dosage , Breast Neoplasms/pathology , Enzyme Inhibitors/administration & dosage , Female , Follicle Stimulating Hormone/analysis , Humans , Luteinizing Hormone/analysis , Middle Aged , Postmenopause , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Tamoxifen/administration & dosage , Triazoles/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...